Vitamins China E-News 1410
出版日期：2014/10/31
頁 數：33頁
文件格式：PDF
價 格：
USD 3,564 (Single-User License)
USD 8,910 (Multi-User License)
USD 8,910 (Multi-User License)
China is the largest vitamin manufacturer and exporter in the world, playing a critical role in the global vitamin market.
Affected by the increasing demand of overseas market, China’s VC export volume rises by 12% year on year in Jan.-Aug. 2014. And VE increases by 20%.
As for the domestic market , the price of VC sees a downtrend because of the high inventory. Affected by the weak demand in Q4, the price of VC is expected to maintain low. In a whole, China's VA market riding high than that of last year, is mainly driven by the recovery of the downstream breeding industry. However, the market price of VA is to decline due to the increasing supply and stable demand. After Sept., the market price of VB2 booms thanks to the higher quotation made by the manufacturers led by Guangji Pharmaceutical.
In Oct., Garden Bio-chemical Stock went to public successfully, which is a matter of concern for the domestic vitamin industry. As the largest VD3 manufacturer in China, Garden Bio-chemical benefits from the price rise of VD3 and the higher gross profit margin.
The domestic vitamin industry seems going through merger and acquisition trend. Xinfu Pharmaceutical, the largest VB5 manufacturer in China, merges two subsidiaries for unified management and fast development. Changjiang Industry Investment Group gets the control of Guangji Pharmaceutical to a largest extent with long-term loans. Guanfu Household merges a VE intermediates manufacturer, Nengte Technology, which may have an effect on the competition pattern of domestic VE industry. Would all of these bring new opportunities and challenges to the vitamin industry at home and abroad? Let’s see!
Affected by the increasing demand of overseas market, China’s VC export volume rises by 12% year on year in Jan.-Aug. 2014. And VE increases by 20%.
As for the domestic market , the price of VC sees a downtrend because of the high inventory. Affected by the weak demand in Q4, the price of VC is expected to maintain low. In a whole, China's VA market riding high than that of last year, is mainly driven by the recovery of the downstream breeding industry. However, the market price of VA is to decline due to the increasing supply and stable demand. After Sept., the market price of VB2 booms thanks to the higher quotation made by the manufacturers led by Guangji Pharmaceutical.
In Oct., Garden Bio-chemical Stock went to public successfully, which is a matter of concern for the domestic vitamin industry. As the largest VD3 manufacturer in China, Garden Bio-chemical benefits from the price rise of VD3 and the higher gross profit margin.
The domestic vitamin industry seems going through merger and acquisition trend. Xinfu Pharmaceutical, the largest VB5 manufacturer in China, merges two subsidiaries for unified management and fast development. Changjiang Industry Investment Group gets the control of Guangji Pharmaceutical to a largest extent with long-term loans. Guanfu Household merges a VE intermediates manufacturer, Nengte Technology, which may have an effect on the competition pattern of domestic VE industry. Would all of these bring new opportunities and challenges to the vitamin industry at home and abroad? Let’s see!
China's VA Market Riding High After an Extraordinary 2014
China’s Breeding Industry Recovers in Q3 2014
Retail Prices of Vitamin Tablets with Same Specification Differ Considerably
Guanfu Household Takes Over VE Intermediate Producer
Garden Bio-chemical Listed in Shenzhen Stock Exchange GEM
Changjiang Industry Investment Group Lends Money to Guangji Pharmaceutical
Xinfu Pharmaceutical Entering into Fast Development Period by Combining Two Subsidiaries
Chinese Vitamins Imp. & Exp., Aug. 2014
Exports of China's VC Rising in Jan.- Aug. 2014
China’s VE Witnesses YoY decline in Export Price during Jan.–Aug. 2014
Price Update of Vitamins, Oct. 2014
VC Price Declines in Q3 2014
VB2 Price Increases Sharply in Sept. 2014
Market price of VD3 Keeps Increasing from July to Mid-October 2014
Market Price of Folic acid Maintains Uptrend Since Jan. 2014
Brother Enterprises Shows Good Performance in Q3
Zhejiang Medicine Merges Changhai Biology
Guangji Pharmaceutical Forecasts Loss in First Three Quarters of 2014
VD3 Content Exceeding Standard
Tiger Industrial Obtains Subsidy
Red Bull’s New Projects Passing Environmental Assessment
Golden Launches Nutritional Gel
Tianxin Pharmaceutical Expands Production of Vitamins
China’s Breeding Industry Recovers in Q3 2014
Retail Prices of Vitamin Tablets with Same Specification Differ Considerably
Guanfu Household Takes Over VE Intermediate Producer
Garden Bio-chemical Listed in Shenzhen Stock Exchange GEM
Changjiang Industry Investment Group Lends Money to Guangji Pharmaceutical
Xinfu Pharmaceutical Entering into Fast Development Period by Combining Two Subsidiaries
Chinese Vitamins Imp. & Exp., Aug. 2014
Exports of China's VC Rising in Jan.- Aug. 2014
China’s VE Witnesses YoY decline in Export Price during Jan.–Aug. 2014
Price Update of Vitamins, Oct. 2014
VC Price Declines in Q3 2014
VB2 Price Increases Sharply in Sept. 2014
Market price of VD3 Keeps Increasing from July to Mid-October 2014
Market Price of Folic acid Maintains Uptrend Since Jan. 2014
Brother Enterprises Shows Good Performance in Q3
Zhejiang Medicine Merges Changhai Biology
Guangji Pharmaceutical Forecasts Loss in First Three Quarters of 2014
VD3 Content Exceeding Standard
Tiger Industrial Obtains Subsidy
Red Bull’s New Projects Passing Environmental Assessment
Golden Launches Nutritional Gel
Tianxin Pharmaceutical Expands Production of Vitamins
